Groowe Groowe / Newsroom / ONC
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ONC News

BeOne Medicines Ltd. American Depositary Shares

L'FDA statunitense concede la revisione prioritaria a TEVIMBRA di BeOne Medicines nel trattamento di prima linea dell'adenocarcinoma gastroesofageo HER2 positivo

businesswire.com
ONC

L'FDA statunitense concede la revisione prioritaria a TEVIMBRA di BeOne Medicines nel trattamento di prima linea dell'adenocarcinoma gastroesofageo HER2 positivo

businesswire.com
ONC

La FDA de Estados Unidos otorga revisión prioritaria a TEVIMBRA de BeOne Medicines en primera línea para HER2+ GEA

businesswire.com
ONC JAZZ

A FDA dos EUA concede revisão prioritária ao TEVIMBRA da BeOne Medicines para o tratamento de primeira linha do adenocarcinoma gastroesofágico HER2+

businesswire.com
ONC

美國FDA授予BeOne Medicines的TEVIMBRA用於HER2陽性胃食管腺癌一線治療的優先審評資格

businesswire.com
ONC

La FDA américaine accorde une évaluation prioritaire au TEVIMBRA de BeOne Medicines dans le traitement de première intention de l’adénocarcinome gastro-œsophagien HER2+

businesswire.com
ONC

Die US-amerikanische FDA bewilligt die vorrangige Prüfung von TEVIMBRA von BeOne Medicines als Erstlinienbehandlung bei HER2+ GEA

businesswire.com
ONC

Amerikaanse FDA kent Priority Review toe aan BeOne Medicines’ TEVIMBRA in eerstelijns HER2+ GEA

businesswire.com
ONC

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

businesswire.com
ONC

Form 8-K

sec.gov
BEIGF ONC